세계의 간질성 폐질환 시장 보고서(2025년)

Interstitial lung disease (ILD) refers to a group of lung conditions that affect the interstitium, the tissue and space surrounding the alveoli in the lungs. The interstitium is crucial for maintaining the structural integrity and function of the lungs, facilitating the exchange of gases between the lungs and the bloodstream.

The primary types of drugs used in the treatment of interstitial lung disease include oral corticosteroids, immunosuppressive medications, anti-fibrotic drugs, and others. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a specific type of interstitial lung disease (ILD) that affects the interstitium, the tissue supporting the air sacs (alveoli) in the lungs. These drugs are indicated for the treatment of various ILD conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The interstitial lung disease market research report is one of a series of new reports from The Business Research Company that provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with an interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interstitial lung disease market size has grown strongly in recent years. It will grow from $1.97 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to awareness and diagnosis improvement, immune system modulation therapies, respiratory rehabilitation programs, multidisciplinary care teams.

The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $2.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to precision medicine, novel drug development, regenerative medicine, telehealth and remote monitoring. Major trends in the forecast period include advancements in imaging technology, ai in imaging, fibrosis subtype differentiation, supportive care services.

The forecast of 7.8% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of antifibrotic medications and portable oxygen concentrators sourced from Switzerland and China, exacerbating respiratory therapy expenses and limiting treatment adherence. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of allergic conditions is expected to drive the growth of the interstitial lung disease (ILD) market in the future. An allergic condition occurs when the immune system overreacts to a substance, known as an allergen, that is typically harmless. Such allergic reactions can lead to ILD, specifically hypersensitivity pneumonitis, where an allergic response causes inflammation in the lungs. For example, in November 2023, the National Asthma Council, an Australia-based organization focused on asthma care, reported 467 asthma-related deaths in 2022, which included 299 females and 168 males. This represents an increase from 355 deaths in 2021. The rise in allergic diseases is contributing to the growth of the interstitial lung disease market. Therefore, the growing prevalence of allergic conditions is accelerating the expansion of the ILD market.

The rising incidence of autoimmune disorders is anticipated to fuel the growth of the interstitial lung disease market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's healthy tissues and cells. The increasing number of autoimmune conditions is contributing to the growth of the ILD market by boosting demand for ILD-related healthcare services, advancing research and development, and driving improvements in treatments and patient care. For example, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research organization, projected that global cases of rheumatoid arthritis will rise to 31.7 million by 2050, reflecting a significant increase over this period. As a result, the rising incidence of autoimmune diseases is propelling the growth of the interstitial lung disease market.

Leading companies in the interstitial lung disease market are focusing on trends such as the introduction of innovative therapies for various conditions, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive lung disease characterized by the scarring of lung tissue, which results in breathing difficulties and decreased oxygen exchange. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical company based in Germany, received FDA approval for its BI 1015550 therapy for the treatment of IPF. BI 1015550 is an investigational oral medication that targets and inhibits phosphodiesterase 4B (PDE4B), providing antifibrotic and anti-inflammatory effects designed to slow the decline in lung function in patients with IPF.

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. This strategic acquisition is aimed at strengthening Merck & Co.'s immunology drug pipeline as it faces the looming loss of exclusivity for some of its top-selling products in the coming years. Prometheus Biosciences Inc., a US-based biotechnology company, specializes in developing therapeutic and complementary diagnostic products for the management of immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Interstitial Lung Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interstitial lung disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for interstitial lung disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interstitial lung disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Oral Corticosteroids; Immune Suppressing; Anti-Fibrotic Medication; Other Drugs
• 2) By Disease Type: Interstitial Pneumonia; Idiopathic Pulmonary Fibrosis; Nonspecific Interstitial Pneumonitis; Hypersensitivity Pneumonitis; Cryptogenic Organizing Pneumonia (COP); Sarcoidosis; Acute Interstitial Pneumonitis
• 3) By Application: Adults; Children
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Oral Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
• 2) By Immune Suppressing: Azathioprine; Methotrexate; Mycophenolate Mofetil
• 3) By Anti-Fibrotic Medication: Pirfenidone; Nintedanib
• 4) By Other Drugs: Antioxidants; Anticoagulants; Other Novel Therapies
• Companies Mentioned: Roche Laboratories Inc.; Merck & Co. Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; The Bristol-Myers Squibb Company; Amgen Inc.; Boehringer Ingelheim; Siemens Healthineers; Koninklijke Philips N.V.; Teva Pharmaceuticals USA Inc.; AstraZeneca plc; Horizon Pharma USA Inc.; Genentech Inc.; Amneal Pharmaceuticals LLC; Fujirebio Diagnostics Inc.; Insmed Inc.; VIDA Diagnostics Inc.; EmphyCorp Inc.; Verseau Therapeutics; Regend Therapeutics Co.; LTT Bio-Pharma Co. Ltd.; Galecto Biotech; Pulmatrix Inc.; PureTech Health plc; Pneuma Respiratory Inc.; Bellerophon Therapeutics Inc.; MediciNova Inc.; Altavant Sciences Inc.; Verona Pharma plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Interstitial Lung Disease Market Characteristics

3. Interstitial Lung Disease Market Trends And Strategies

4. Interstitial Lung Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Interstitial Lung Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Interstitial Lung Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Interstitial Lung Disease Market Growth Rate Analysis
• 5.4. Global Interstitial Lung Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Interstitial Lung Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Interstitial Lung Disease Total Addressable Market (TAM)

6. Interstitial Lung Disease Market Segmentation

• 6.1. Global Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroids
• Immune Suppressing
• Anti-Fibrotic Medication
• Other Drugs
• 6.2. Global Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interstitial Pneumonia
• Idiopathic Pulmonary Fibrosis
• Nonspecific Interstitial Pneumonitis
• Hypersensitivity Pneumonitis
• Cryptogenic Organizing Pneumonia (COP)
• Sarcoidosis
• Acute Interstitial Pneumonitis
• 6.3. Global Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Children
• 6.4. Global Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Interstitial Lung Disease Market, Sub-Segmentation Of Oral Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• 6.6. Global Interstitial Lung Disease Market, Sub-Segmentation Of Immune Suppressing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azathioprine
• Methotrexate
• Mycophenolate Mofetil
• 6.7. Global Interstitial Lung Disease Market, Sub-Segmentation Of Anti-Fibrotic Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pirfenidone
• Nintedanib
• 6.8. Global Interstitial Lung Disease Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antioxidants
• Anticoagulants
• Other Novel Therapies

7. Interstitial Lung Disease Market Regional And Country Analysis

• 7.1. Global Interstitial Lung Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Interstitial Lung Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Interstitial Lung Disease Market

• 8.1. Asia-Pacific Interstitial Lung Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Interstitial Lung Disease Market

• 9.1. China Interstitial Lung Disease Market Overview
• 9.2. China Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Interstitial Lung Disease Market

• 10.1. India Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Interstitial Lung Disease Market

• 11.1. Japan Interstitial Lung Disease Market Overview
• 11.2. Japan Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Interstitial Lung Disease Market

• 12.1. Australia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Interstitial Lung Disease Market

• 13.1. Indonesia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Interstitial Lung Disease Market

• 14.1. South Korea Interstitial Lung Disease Market Overview
• 14.2. South Korea Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Interstitial Lung Disease Market

• 15.1. Western Europe Interstitial Lung Disease Market Overview
• 15.2. Western Europe Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Interstitial Lung Disease Market

• 16.1. UK Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Interstitial Lung Disease Market

• 17.1. Germany Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Interstitial Lung Disease Market

• 18.1. France Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Interstitial Lung Disease Market

• 19.1. Italy Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Interstitial Lung Disease Market

• 20.1. Spain Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Interstitial Lung Disease Market

• 21.1. Eastern Europe Interstitial Lung Disease Market Overview
• 21.2. Eastern Europe Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Interstitial Lung Disease Market

• 22.1. Russia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Interstitial Lung Disease Market

• 23.1. North America Interstitial Lung Disease Market Overview
• 23.2. North America Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Interstitial Lung Disease Market

• 24.1. USA Interstitial Lung Disease Market Overview
• 24.2. USA Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Interstitial Lung Disease Market

• 25.1. Canada Interstitial Lung Disease Market Overview
• 25.2. Canada Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Interstitial Lung Disease Market

• 26.1. South America Interstitial Lung Disease Market Overview
• 26.2. South America Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Interstitial Lung Disease Market

• 27.1. Brazil Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Interstitial Lung Disease Market

• 28.1. Middle East Interstitial Lung Disease Market Overview
• 28.2. Middle East Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Interstitial Lung Disease Market

• 29.1. Africa Interstitial Lung Disease Market Overview
• 29.2. Africa Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Interstitial Lung Disease Market Competitive Landscape And Company Profiles

• 30.1. Interstitial Lung Disease Market Competitive Landscape
• 30.2. Interstitial Lung Disease Market Company Profiles
  • 30.2.1. Roche Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis Pharmaceuticals Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Interstitial Lung Disease Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Boehringer Ingelheim
• 31.3. Siemens Healthineers
• 31.4. Koninklijke Philips N.V.
• 31.5. Teva Pharmaceuticals USA Inc.
• 31.6. AstraZeneca plc
• 31.7. Horizon Pharma USA Inc.
• 31.8. Genentech Inc.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Fujirebio Diagnostics Inc.
• 31.11. Insmed Inc.
• 31.12. VIDA Diagnostics Inc.
• 31.13. EmphyCorp Inc.
• 31.14. Verseau Therapeutics
• 31.15. Regend Therapeutics Co.

32. Global Interstitial Lung Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Interstitial Lung Disease Market

34. Recent Developments In The Interstitial Lung Disease Market

35. Interstitial Lung Disease Market High Potential Countries, Segments and Strategies

• 35.1 Interstitial Lung Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Interstitial Lung Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Interstitial Lung Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer